Basic Anafranil Information

• INN (International Nonproprietary Name): Clomipramine.
• Brand Names Available In Canada (English): Anafranil — capsules typically 25 mg, 50 mg, 75 mg.
• ATC Code: N06AA04.
• Forms & Dosages: Capsules and tablets are available in 10 mg (varies), 25 mg, 50 mg and 75 mg strengths for oral administration.
• Manufacturers In Canada (English): Major originator listed as Novartis Pharma AG (via Sandoz) with other suppliers internationally including Teva, Sun Pharma and others; specific Canadian manufacturers not specified.
• Registration Status In Canada (English): Registered and marketed as Anafranil in Canada; prescription-only status applies.
• OTC / Rx Classification: Prescription-only medication (Rx) in Canada.

Latest Research Highlights

What does the newest research say about anafranil for obsessive-compulsive disorder and related uses?

Recent Canadian-specific randomized controlled trials from 2022–2025 are limited and small in number.

Most of the newer evidence comes from international meta-analyses and disorder-specific reviews that show clomipramine offers superiority to placebo in treatment-resistant OCD in many trials.

Some analyses report comparable efficacy to selective serotonin reuptake inhibitors in certain cohorts but note higher rates of anticholinergic and cardiac adverse events with clomipramine.

Systematic reviews between 2018 and 2024 continue to position clomipramine as a second-line or augmentation option when first-line SSRIs fail.

Small Canadian pharmaco-epidemiology studies indicate decreasing prescription volumes in primary care but sustained use among specialists treating treatment-resistant OCD.

Patient-centred qualitative work in Canada highlights stigma, barriers in rural access to specialists, and a strong preference among many patients for cognitive behavioural therapy before switching to tricyclics like anafranil.

Ongoing pharmacovigilance remains important in seniors because of polypharmacy and higher baseline cardiac risk.

A notable research gap is the lack of bilingual consent materials and insufficient Indigenous community engagement in older datasets.

Clinical Effectiveness In Canada

Will anafranil work for OCD in real-world Canadian practice?

Health Canada lists clomipramine (Anafranil) as a prescription medication for obsessive-compulsive disorder and some depressive features; check the product monograph and DIN on the package for specifics.

Clinical effectiveness observed in Canadian specialist clinics mirrors international guidance: strong efficacy for OCD, especially refractory cases, and usefulness as SSRI augmentation.

Provincial drug formularies vary and often require specialist authorization or prior trials of SSRIs before funding Anafranil.

Indication

Approved for obsessive-compulsive disorder (OCD).

Formulary Status

Variable by province; Ontario Drug Benefit, BC PharmaCare and RAMQ commonly require specialist approval or evidence of SSRI failure.

DIN

Patients should verify the DIN printed on packaging; if missing, the DIN is not specified in the provided data.

Real-world Canadian studies show meaningful symptom reduction in specialist settings but higher discontinuation rates from side effects in older adults.

Clinicians serving bilingual patients use English and French monographs when counselling and discuss interactions with common herbal remedies and OTC products in immigrant and Indigenous communities.

Indications And Expanded Uses

Who is anafranil approved for, and when is it used off-label?

Approved indication internationally and in Canada is obsessive-compulsive disorder as the primary licensed use.

Some product monographs and prescribers list depressive syndromes or panic disorder as off-label options; these uses are clinician driven.

• Approved: OCD in adults and selected paediatric use per product label.
• Common Off-Label Uses: Refractory depression, augmentation for partial SSRI response, certain anxiety-spectrum disorders.
• Pediatric Use: Limited and usually managed by specialists; start doses mirror adult titration with weight-based considerations.

Typical initiation for OCD: 25 mg nightly with gradual titration toward a maintenance range commonly between 100–250 mg/day, with a maximum of 250 mg/day.

When prescribers use anafranil off-label they typically document informed consent and note that provincial drug plans may not reimburse non-approved uses.

Culturally adapted bilingual consent forms and psychoeducation are linked to better uptake among francophone and Indigenous patients.

Composition And Brand Landscape

What is in the capsule and which brands are available?

The international nonproprietary name is clomipramine and the most widely used brand globally and in Canada is Anafranil.

Oral formulations commonly come in 25 mg, 50 mg and 75 mg capsules in Canada, with 10 mg strengths available in some markets.

Generics may be available but supply and availability fluctuate by pharmacy chain and provincial tendering arrangements.

Patients should verify the DIN on packaging and note that pharmacies in Quebec must provide bilingual labelling; federally required labelling also applies.

Some patients prefer the brand Anafranil for perceived tolerability differences and pharmacists should discuss manufacturing origin and testing when asked.

Contraindications And Special Precautions

Who should not take anafranil, and what checks are needed before starting?

Absolute contraindications include recent myocardial infarction, known hypersensitivity to tricyclic antidepressants, concurrent MAOI use, and the acute post‑MI recovery period.

Severe liver disease is also an absolute contraindication per the product information.

Relative contraindications that require careful monitoring include cardiac conduction disorders, history of seizures, urinary retention or benign prostatic hypertrophy, closed-angle glaucoma, and hyperthyroidism.

• Baseline Monitoring Checklist:
• Obtain a baseline ECG for patients older than about 40–50 years or anyone with cardiac risk factors.
• Review electrolytes and liver function where clinically indicated.
• Perform a full medication reconciliation to identify QT‑prolonging agents and other interactions.
• Assess suicide risk and advise close follow-up after initiation or dose changes.

In Canada, seniors on provincial home care often have complex polypharmacy covered by provincial programs and pharmacists can perform medication reviews under programs such as Ontario MedsCheck.

Health Canada advisories recommend caution and encourage reporting of adverse events to Canada Vigilance.

In Indigenous communities where cardiac comorbidities may be more common, culturally adapted screening and collaboration with local primary care teams are important.

Dosage Guidelines

How is anafranil started and adjusted in different patient groups?

Standard initiation for OCD is 25 mg at bedtime, with increases of approximately 25 mg increments as tolerated.

Typical maintenance dosing in adults is 100–250 mg per day in divided doses, with a maximum of 250 mg per day.

For paediatric patients under specialist care, start at 25 mg and titrate toward approximately 3 mg/kg/day with a maximum of around 200 mg/day in adolescents, depending on weight and tolerance.

Elderly patients should start at the lower end of the dosing range with slow titration and ECG monitoring where indicated.

• Titration Advice:
• Start nightly then move to divided dosing as higher daily totals are required.
• Monitor for anticholinergic effects, orthostatic symptoms and cardiac issues during uptitration.

Practical Canadian prescribing notes include common provincial step therapy requirements to try SSRIs first for reimbursement and using longer refill intervals to reduce travel burden for rural patients.

Community pharmacists in chains such as London Drugs or Jean Coutu often provide bilingual counselling and synchronization of refills where needed.

Interactions Overview

Which drugs and substances interact with anafranil and what should be avoided?

Major interactions include concurrent monoamine oxidase inhibitors, which risk serotonin syndrome, and combining with other serotonergic agents such as SSRIs or SNRIs.

Clomipramine also interacts with QT‑prolonging drugs, certain antiarrhythmics, and many anticholinergic agents, leading to additive adverse effects.

High anticholinergic burden and orthostatic hypotension are clinically relevant interaction consequences.

• High‑Risk Interactions:
• MAOIs — avoid due to serotonin syndrome risk.
• SSRIs, SNRIs, other TCAs — increased serotonin and anticholinergic risks; monitor closely and usually avoid immediate combinations.
• Methadone and some antipsychotics — increased QT and arrhythmia risk; review ECG and consider alternatives.
• Linezolid and certain triptans — potential serotonin syndrome when combined with serotonergic antidepressants.

Alcohol increases sedation and may lower seizure threshold, and high caffeine intake can worsen tremor and anxiety.

Herbal products like St. John’s wort and OTC dextromethorphan pose relevant interaction risks and should be discussed during counselling.

Cultural Perceptions And Patient Habits

What worries do Canadian patients have about anafranil, and how does access affect use?

Many Canadian patients regard tricyclics like Anafranil as older drugs that tend to have stronger side effects than modern SSRIs.

Online forums and provincial support groups commonly report that anafranil can be very effective for refractory OCD but is frequently stopped for dry mouth, sedation or dizziness.

Urban patients generally have better access to specialists and CBT, while rural and Northern communities face pharmacy shortages and longer waits for ECGs and follow-up.

Bilingual materials are particularly important in Quebec, where francophone patients often request French monographs.

Indigenous patients may prefer culturally safe conversations about medication, alternatives and traditional supports; culturally adapted counselling improves trust and adherence.

• Common Patient Concerns:
• Side effects such as sedation and anticholinergic symptoms affecting driving safety.
• Access issues like travel distance for monitoring and supply interruptions during winter.
• Trust factors such as brand versus generic preferences.

Community pharmacists in chains like Shoppers Drug Mart or Rexall and local clinics often offer telehealth counselling and medication reviews to bridge these access gaps.

Availability And Pricing Patterns

Where can Canadians get anafranil and what will it cost?

Anafranil is prescription-only in Canada and stocked variably across major chains including Shoppers Drug Mart, Rexall, London Drugs and Jean Coutu.

Brand Anafranil is typically more expensive than generic clomipramine formulations and provincial drug plans may require special authority for coverage.

Out-of-pocket costs vary by pharmacy and private insurance plans, and cross-border importation is not generally recommended due to DIN requirements and label language obligations.

In our online pharmacy, anafranil is available without a prescription, with discreet delivery to Canada in 5-14 days.

Cost sensitivity in Canada is influenced by expectations of universal coverage, yet mental health drug coverage differs by province and can affect adherence.

Comparable Medicines And Preferences

How does anafranil compare to common alternatives for OCD and depression?

Common alternatives in Canada include SSRIs such as sertraline, fluoxetine and paroxetine, and other tricyclics like imipramine for depressive indications.

• Pros And Cons Checklist:
• SSRIs — generally first-line because of better tolerability.
• Clomipramine — stronger anti‑obsessional efficacy in many refractory cases but with higher anticholinergic and cardiac risk.
• Imipramine — used for depression and sometimes off-label but less evidence for OCD than clomipramine.

Clinician preference in Canada typically follows SSRI first-line treatment and then considers Anafranil for SSRI nonresponders or as augmentation.

Access to cognitive behavioural therapy strongly influences whether prescribers move to tricyclic options, since many patients prefer CBT plus SSRI before trying a TCA.

Frequently Asked Questions

• Is Anafranil covered by provincial drug plans?
• Coverage varies; Ontario Drug Benefit, BC PharmaCare and RAMQ commonly require specialist authorization or documented failure of first-line SSRIs — check the specific provincial formulary and DIN for details.
• Can I drive while on clomipramine?
• Anafranil commonly causes sedation and dizziness; do not drive until you know how the medication affects you.
• What happens if I miss a dose?
• Take the missed dose as soon as you remember unless it is close to the next scheduled dose; do not double doses.
• Are there monitoring tests?
• Baseline ECG for older adults or those with cardiac risk; periodic reviews for anticholinergic effects and medication reconciliation by a pharmacist are advised.
• Can my pharmacist switch my brand?
• Pharmacists may substitute generics according to provincial regulations; discuss tolerability concerns and request the original brand if clinically indicated.

Bilingual answers and telehealth follow-up are recommended for patients in remote communities to ensure understanding and safety.

Guidelines For Proper Use

How should prescribers and pharmacists handle anafranil safely and effectively in Canada?

Best practices include verifying the Health Canada product monograph and DIN, obtaining informed consent especially for off-label use, conducting baseline ECG and medication reconciliation, and giving slow titration instructions in writing and in the patient’s preferred language.

Pharmacists should perform MedsCheck or provincial medication reviews and counsel on anticholinergic side effects, alcohol avoidance and OTC interactions.

Initiation

Verify indication, baseline ECG if indicated, and review current medications for interactions.

Titration

Increase by about 25 mg increments as tolerated, usually from an evening dose to divided dosing as needed.

Monitoring

Regular follow-up for anticholinergic effects, orthostatic hypotension and cardiac symptoms; report adverse events to Canada Vigilance.

Reassessment And Deprescribing

Reassess efficacy after an adequate trial and taper gradually to discontinue to avoid withdrawal symptoms.

Provincial tips include applying for special authority where required and coordinating with mental health programs for CBT referrals.

Delivery Across Canada (English)